Lincoln Pharmaceuticals Ltd · NSE:LINCOLN
Lincoln Pharmaceuticals — Q1 FY2018 Earnings Presentation
20 slides from Lincoln Pharmaceuticals's earnings presentation, 2017
Slide 1: Q1 FY2018 Earnings Presentation
Q1 FY2018 Earnings Presentation Providing Affordable and Innovative medicines for healthier lives
Slide 2: Highlights
Highlights Q1 FY2018 vs. Q1 FY2017 Management Perspective Performance of the Company during the quarter was impacted by o Net Revenue of Rs. 1,377 million the prevailing regulatory challenges and GST-led de stocking in the domestic market. Despite unfavorable industry scenario, we are o EBITDA of Rs
Slide 3: Performance Overview
Performance Overview Consolidated Financial Performance Q1 y-o-y Particulars FY2018 FY2017 Growth (%) Net Revenue 1,377 927 48.5% EBITDA 99 186 (47.1)% Margin (%) 7.2% 20.1% PBT 69 151 (54.6)% Margin (%) 5.0% 16.3% Profit After Tax (PAT) 49 114 (57.1)% Margin (%) 3.6% 12.3% Basic EPS (Rs.) 2.45 6.99
Slide 4: Performance Overview: Revenue Breakup
Performance Overview Revenue Breakup 2% 1%2% 1% General Anti Infectives 14% 0.6% 1.8% 0.9% 25% 17.9% 2.1% Respiratory Systems Therapeutic Area 26.7% 14.0% 24.9% Parasitology 19% 0.4% 1.3% Alimentary Tract and Metabolism 1.9% 14% 16% Musculo-Skeletal System 3.7% Q1 FY2018 6% Q1 FY2017 Genito Urinary
Slide 5: Performance Trend
Performance Trend Net Revenue (Rs. million) and Y-o-Y Growth (%) Q1 FY2018 Highlights (Y-o-Y) 48.5% 22.5% o Revenue growth supported by increasing (18.6)% (6.9)% demand from General Anti Infectives and (31.9)% 927 777 735 1,196 1,377 Parasitology segments Q1 FY17 Q2 FY17 Q3 FY17 Q4 FY17 Q1 FY18 o Pr
Slide 6: Performance Trend
Performance Trend Net Debt / LTM EBITDA Total Debt / Net Worth 0.5x 1.2x 0.4x 1.0x 1.0x 0.9x 0.3x 0.3x 0.3x 0.7x Q1 FY17 Q2 FY17 Q3 FY17 Q4 FY17 Q1 FY18 Q1 FY17 Q2 FY17 Q3 FY17 Q4 FY17 Q1 FY18 ROCE1 RONW2 23.6% 18.5% 19.0% 22.1% 21.4% 16.6% 16.1% 13.0% 13.9% 10.7% Q1 FY17 Q2 FY17 Q3 FY17 Q4 FY17 Q1
Slide 7: Leverage Profile
Leverage Profile (Rs. million) June 30th, 2017 June 30th, 2016 Long Term Debt 174 183 Credit Rating Short Term Debt 423 528 o The Company’s debt facilities have been assigned Total Debt 597 711 the following ratings by CRISIL Long term bank facilities: A- Less: Cash & Cash Equivalents 122 143 Sh
Slide 8: Recent Developments
Recent Developments 1 Delisting of Equity Shares from Ahmedabad Stock Exchange • The Company applied for voluntary delisting from the Ahmedabad Stock Exchange Limited (ASEL) and was granted approval. The equity shares of the Company were delisted from ASEL w.e.f. 24th November, 2016 2 Developed new
Slide 9: Research & Development
Research & Development Research Facilities R&D Expenditure (Rs. mn) and as % of Sales 2.4% 2.0% 2.7% 88 1.6% 80 Senior Scientist 15 73 Junior Scientist 18 Analysts 18 Regulatory Personnel 12 34 Administrative Personnel 9 Others 6 Total 78 FY14 FY15 FY16 FY17 9
Slide 10: A Leading Pharmaceutical Company
A Leading Pharmaceutical Company Research & Development Department Market Presence Presence in 4 Patents Granted 773 Registered Dossiers 15+ 60+ 25 Patents Applications 580 Ongoing Applications Countries Therapeutic Areas 300+ 44th Formulations Developed Rank in AIOCD 550 Field Staff 22 C&F Agents J
Slide 11: Key Milestones
Key Milestones Received WHO – Becomes Public Covered 80% of all Developed & Launched Robust business growth in GMP for plant / Limited Company India Market 3 NDDS products domestic & international production unit from a Partnership markets 2016-17 2015-16 2014-15 2010-11 2001 2000 1997-98 1995-96 19
Slide 12: Global Footprint
Global Footprint Presence over 60 countries in Europe, Latin America, Africa, Asia Pacific and South East Asia; 22 states across India Jammu Uttaranchal Chandigarh Delhi Europe: Ambala Ghaziabad France Lucknow Guwahati Jaipur Patna Ranchi Ahmedabad Kolkata Indore Raipur Nagpur Cuttack Vijayawada Che
Slide 13: Best-in-Class Facilities
Best-in-Class Facilities Certifications: WHO-GMP Certified; ISO9001:2008 Certified R&D Center: Approved by Government of India; Team of 30 scientists for R&D Green Energy: Windmill project for captive consumption Dosage Forms Produced at Unit 1 Dosage Forms Produced at Unit 2 Description Annual Capa
Slide 14: Wide Spectrum of Therapeutic Coverage
Wide Spectrum of Therapeutic Coverage Cough & Cold / Sterile Ophthalmic Dermatologist Gyneacologial Gastro Intestinal Anti Allergic / Anti- Eye Preparation Products Range asthmatics Drops/Ointment Anti-bacterial / Vitamins / Minerals Analgesic / Anti- Anti-diuretics/ Anti-malarial Anti-viral/ Anti-
Slide 15: Key Brands
Key Brands Domestic Market International Market Calcium Carbonate 1250 mg+ 11 Antioxidants + 33 Essential Micronutrients + Each squirts (spray) delivers 2 Vit. D3 250 I.U. Tablets 5 Amino Acids mg Ondansetron Hydrochloride α-β Arteether Injection Artesunate for Injection 60 mg Anti Cold Capsules 150
Slide 16: Key Recent Developments
Key Recent Developments o Progesterone spray • Unique delivery system for accurate 25mg delivery of micronized progesterone/Spray • Formulation dispensed in mist form which provides local as well as systemic effect of Progesterone via vaginal route covering large area of vaginal cavity • Better pati
Slide 17: Key Recent Developments
Key Recent Developments o Arteether injection 150 mg/ml • Unique low-viscosity sterile formulation for malaria • Less painful and low volume (1 ml) IM formulation • Convenient patient administration • Patented technology o Namcold DX • First time in India: ‘Extended Release’ Oral Suspension • The on
Slide 18: Key Recent Developments
Key Recent Developments o Diclofenac Rectal Spray • First time in India liquid formulation for rectal use • Better absorption compare to suppository • Higher Concentration achieve for analgesic effect • Meter dosage deliver accurate dose 18
Slide 19: Disclaimer
Disclaimer This presentation contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Lincoln Pharmaceuticals’ future business developments and economic perfor
Slide 20: Corporate Office
CORPORATE OFFICE LINCOLN HOUSE B/h. Satyam Complex, Science City Road, Sola, Ahmedabad – 380 062. Gujarat, INDIA. Phone :+91-79-67778000 • Fax:+91-79-67778062 E-mail:info@lincolnpharma.com www.lincolnpharma.co.in KP Sompura, Finance Head sompurakp@lincolnpharma.com Lincoln Pharmaceuticals +91 79 677
Lincoln Pharmaceuticals — Q1 FY2018 Earnings Presentation on 6ix